Home » #biogen

Tag: #biogen

Facebook, Alphabet, Tesla, Intel, Biogen, Gilead, Oil - The Daily Rundown June 18

Facebook, Alphabet, Tesla, Intel, Biogen, Gilead, Oil – The Daily Rundown June 18



Facebook, Alphabet, Tesla, Intel, Biogen, Gilead, Oil – The Daily Rundown June 18

MICHAEL KRAMER AND THE CLIENTS OF MOTT CAPITAL OWN SHARES OF TSLA AND GOOGL
© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Join our 611 Daily Subscribers And Get This FREE Commentary In Your E-Mail! 

 

The stock market had another back and forth session with the S&P 500 trading lower on the day, but it was Technology, Energy, and Biotech that finished the day in the green. S&P 500 continues to demonstrate a substantial amount of resilience testing and retesting support at 2,760.

Facebook

Big-cap technology continues to rally with shares of Facebook rising to nearly $200. The trend for Facebook remains strong,  with no obvious signs of slowing down. We should remember quarter end is fast approaching, and some of these companies may see a considerable boost in prices in anticipation of strong results.  Remember Facebook trades at a relatively cheap one-year forward PE ratio of 22.3.

Facebook


Alphabet

Alphabet shares crossed over resistance at $1170, that should be a  positive sign for the stock continuing its rise. Alphabet is another of these technology giants with a reasonable valuation at 24.7 times 2019 earnings estimates.

alphabet

Tesla

Tesla crossed over $363, and that may pave the way for a rise back to the all-times around $385. I have no idea what is going on with all these email leaks at the company it is kind of crazy. Elon might be better off just posting them all on Twitter at this point.

It is a joke, to be honest, and I can’t understand how that happens.

Part of me is playing the skeptic with the latest run of corporate espionage and sabotage at Tesla; I’m just praying they aren’t setting this up to have a scapegoat if they don’t hit 5,000 Model 3’s per week.

tesla

Intel

But not all was positive with shares of Intel falling to the uptrend.  We have been talking about this one for some time with the bearish setup. I’m just wondering how much more there is to drop or if this is the bottom,  I can make a case for both a further fall or bounce back.

Biogen

The large-cap biotech stocks struggled today, with Biogen getting hit after a competitor released positive results in a trial result.   The stock is in limbo right now, and I can see it easily refilling the gap up at $300, or falling further to $280.

biogen

Advertisements

Gilead

Gilead continues to struggle, and finally, the buyers gave up at $72, and shares are trending lower with the potential to fall back to $66.75. There is nothing to like about this stock, technical or fundamentally. Sorry folks. I’m not into that whole declining revenue and earnings thing. I love companies that are growing, not shrinking.

I know it only trades at 10.6 times 2019 earnings estimates of $6.46 per share. But…

Its earnings are expected to fall by over 30 percent in 2018, and its revenue is set to drop by over 21 percent! Then, of course, we get the huge bounce back in 2019, with earnings climbing a massive 5 percent, on 1.5 percent revenue growth. It is overvalued even at 10.6 times 2019 earnings.

I’m just trying to help, don’t hate on me. Maybe I will be wrong. I’d love for the stock to go up for the long holders, but the company needs to do more to reignite growth, and buying Kite was not enough.

By the way, I have zero, no, none positions in Gilead, long/short, calls/puts. Nothing. And haven’t since selling it around $100 in April of 2016.

Gilead

AT&T

AT&T Is near a significant support level at $32, and if that cracks, it has further to fall. A lot more to fall.

at&t

Finally, I know Oil was up today, big deal. The chart looks gross.

oil

It is almost as bad as the financials :). Sorry I couldn’t resist.

You know how stupid I will look if the banks actually rise! Geez. Yeah stupid.

banks

Hope you enjoyed!

Night

-Mike

Photo Credit via Flickr

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future. 

#gilead #biogen #oil #alpahbet #facebook #intel #tesla

Advertisements
10 Indicators To Watch In The Stock Market For The Week of May 28 stock to watch

10 Indicators To Watch In The Stock Market For The Week of May 28



10 Indicators To Watch In The Stock Market For The Week of May 28

MICHAEL KRAMER AND THE CLIENTS OF MOTT CAPITAL OWN SHARES OF NFLX & AAPL
© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Join our 611 Daily Subscribers And Get This FREE Commentary In Your E-Mail! 

 

The coming week will be a big week when it comes to data, with inflation and jobs data starting on Wednesday. First, we get ADP private jobs data, with consensus looking for 186,000 jobs created in May, and then 1Q GDP comes later that morning with consensus calling for growth of 2.3 percent. Thursday is personal income and outlays, PCE y/y is expected at 2 percent, while PCE Core ex-food and energy is projected at 1.8 percent. Friday is the employment report, with estimates calling for 185,000 jobs created, and average hourly earnings up 2.7 percent y/y.  You can find more at the Bloomberg calendar, a handy tool.

So, we should expect the week to have a little more volatility following the numbers, each day, but this week will most certainly be all about inflation. When you look at core PCE over the course of the last 10-years, we can see that it has been consistently low.

PCE like the other gauges of inflation, like PPI and CPI, tracks extremely closely to the price of Oil. 

By the way in case you are curious you can see the similarity with oil and PCE ex-food and energy, are not as close.

When it comes to the future of inflation and interest rates, we will need to watch the price of oil. Wages should continue to remain contained as well below 3 percent.

So is it possible that we see some huge spike in inflation worries this week, well anything is possible. Is it likely? I have a decade worth of data saying no. Additionally, one must remember that the data is backward looking, and oil is a real-time barometer of inflation, and so if oil continues to fall come Tuesday, then I suspect rates fall with it, regardless of the reports.


Stocks To Watch

The most important stocks to watch this week, Netflix, Amazon, Apple, Micron, Biogen, Microsoft, P&G, and Coke. Yes P&G and Coke! Really. Remember if rates are falling then the staples, which have been crushed, should see a rotation back into the names. The other stocks are leads in the most important risk-on sectors around, Technology, Chips, and Biotech.

Advertisements

P&G

The chart of P&G is bullish and suggests shares could rise back to $78.20 in the short-term. The relative strength index (RSI) is trending higher and has bottomed out at oversold levels now on two occasions.

PG

Coke

The setup in Coke is quite positive too and looks to be heading back towards to $44.50

coke


Microsoft

Microsoft broke out, and we want to continue to see the stock rise. The relative strength index continues to trend higher as well.

microsoft

Biogen

Biogen has broken out as well, and it could be looking to rise back towards $300.

biogen

Apple

Apple has been consolidating since its post-earnings rally, and a breakout higher from the markets most valuable company, would add to positive sentiment.

apple


Micron

Micron is facing a potentially big breakout. Micron has been one of the hottest stocks around, so we want to see this one continue to stay hot, as it acts as a barometer for the risk appetite of the market.

micron

Amazon

Amazon is knocking on the door of a big breakout too.

amazon

Advertisements

Netflix

There is no doubting that Netflix is the undisputed champion in the market this year, and there is no stock that is more important. If Netflix continues to rise, then I suspect the rest of the market will soon follow.

netflix

Enjoy the long weekend.

-Mike


Advertisements

Just $200 Per Year – Get Your Free 2 Week Trial

Recent Videos:

Oil Down, Yields Down, Dollar Up

Be Careful With Oil, Netflix Breakout

More Positive Signs Develop, Plus Sub Mailbag

The Setup In Stocks Continues To Improve

Getting Long Apple

A Rise Back To 2,800 On The S&P Is In The Works

Free Articles Written By Mike:

Roku’s Battered Stock May Rebound 12%

Walmart’s Stock Faces a 12% Plunge

Nvidia Seen Soaring to Record on Explosive Growth

Netflix Breakout May Lead to 14% Surge

3 Energy Stocks Poised for Big Breakouts

Macy’s Soaring Stock Seen Rising 11% Higher

JPMorgan’s Stock May Rebound to New Record High

3 Stocks Poised to Lead as S&P 500 Breaks Out

Alibaba’s Stock Seen Rising by 18% on Strong Growth

Micron Stock Seen Rising 14% on Raised Forecasts

Big Warning Signs for Starbucks Stock

P&G’s Battered Stock Ready for 10% Rebound

GE’s Breakout May Send Shares 15% Higher

Join our 611 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

Photo credit via Flickr

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #sp500 #inflation #oil #yield #microsoft #apple #netflix #amazon #biogen #micron

Biotech's Stock May Have Finally Been Unleashed

Biotech Stocks May Have Finally Been Unleashed

Biotech Stocks May Have Finally Been Unleashed

Michael Kramer and the Clients of Mott Capital Own CELG
© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Join our 611 Daily Subscribers And Get This FREE Commentary In Your E-Mail! 

 

Stocks continued to move higher, led by the Biotech’s, which were up by about 3 percent. There’s something we haven’t said in a long time. The highly anticipated speech regarding drug prices by the President didn’t seem to be as bad as many had feared. Increasing competition, deregulation, cutting out the middlemen, is at the core of the proposals, based on my interpretation.

The drug pricing overhang had plagued this sector since September 2015, when Hillary Clinton made it a political point in the race for President. If this is the worst of it, I think the group might have much further to rise. Companies like Celgene, Gilead, Biogen, and Amgen are all trading at some of their lowest earnings multiples in years. Albeit for good reasons in some cases, but some of the valuations seem excessively low.

The details aren’t fully known yet, and what ends up getting put into law may be very different. But just knowing the blueprint for how they plan to tackle drug pricing might unleash the sector from the shackles of the past three years.

I think the group is likely heading higher.
biotech


S&P 500

The S&P 500 continues to rally, and finished near the highs at 2727, up about 2.5 percent. The setup continues to look strong.

sp500

Mott Capital Management, Michael Kramer

Mott Capital’s Reading The Markets

An In-depth Global Macro Premium Stock Market Commentary

In Video Format- See How Michael Dissects The Markets

Premium Subscription Based Membership

Just $200 Per Year – Get Your Free 2 Week Trial

Amazon

Technology stocks continue to look strong as well and so do consumer stocks, even though Amazon still didn’t break out.  $1620 is proving, for now, to be tough for Amazon. Now that I’m calling for it to rise, it will probably go down! Ugh. We shall see.

amazon

Advertisements

Nvidia

I’m surprised Nvidia was down today. But I also do not think today’s price actions mean the stock is going lower. Shares held firmly above support around $253. The results were stunning, and this probably keeps working higher.

nvda


Amgen

Amgen shares continue to look strong as well, with a well-defined double bottom, and what looks like a solid path towards $178 to $180 range.

amgen

Advertisements

Gilead

Gilead also looks as if it could see a rise to about $72.

gilead


Biogen

Biogen also looks like it is on the cusp of a big breakout.

biogen

That is going to be it for today.

Mott Capital’s Reading The Markets – An In-depth Global Macro Stock Market Commentary – In Video Format – See How Michael Dissects The Markets

Just $200 Per Year – Get Your Free 2 Week Trial

Recent Videos:

The Setup In Stocks Continues To Improve

Getting Long Apple

A Rise Back To 2,800 On The S&P Is In The Works

Why It Is Time To Dump Starbucks, Plus A Look At ACAD

The Market Continues To Sink

It’s Back! Apple Investors Are Worried Once Again

A Review Of Netflix, IBM And Earnings Outlook

Free Articles Written By Mike:

Broadcom Traders Bet on 12% Rebound

Costco May Plunge 11% as Growth Slows

Square’s Stock Seen Rising 12% By June

Disney’s Stock Is Poised to Rise By 10%

Gilead May Rebound By 12% Short Term

Tesla Stock May Break Out, Fueling a 10% Increase

Alphabet’s Battered Stock May Jump 7% Short Term

3 Overvalued Stocks That May Fall Sharply

3 Tech Stocks Nearing a Breakout

Roku’s Stock Faces Huge 17% Price Swing on Results

Nvidia’s Stock Poised For Big 8% Jump On Earnings

Amazon Traders Bet Stock Will Rise 12% Further

Microsoft Bulls Look for More Big Gains

Why S&P 500 Stocks May Rebound 6% Short Term

Chipmakers May Soon Rebound to New Highs

Biotech Stocks Set to Breakout

Join our 611 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

Photo credit via Flickr

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #biotech #amgen #gilead #biogen #technology #amazon #sp500

twitter amd broadcom biotech

Twitter and AMD Options Stand Out, Is There A Double Top In Biotech?


Twitter and AMD Options Stand Out, Is There A Double Top In Biotech?

The stock market overall had another dull day, with the S&P 500 down less than 10 bps, closing at 2,747. Like I had mentioned yesterday, the S&P managed to hang around support at 2,746. Again, there is a chance we could try for 2,740, but my expectations continue to suggest higher equity price over the short-term.

Mott Capital Management, Michael Kramer

Mott Capital’s Reading The Markets

An In-depth Global Macro Premium Stock Market Commentary

In Video Format- See How Michael Dissects The Markets

Premium Subscription Based Membership

Just $200 Per Year – Get Your Free 2 Week Trial

S&p 500

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Join our 611 Daily Subscribers And Get This FREE Commentary In Your E-Mail! 

 

Yields

10-year treasury yield continue to head lower, and I think they head toward the 2.6 percent region.

10-year


IBB

The NASDAQ Biotech ETF, $IBB, looks headed towards $111.50, where there is a steady level of support there. If that cracks, we have much lower to go, and it makes the downtrend more powerful.

biotech


XBI

The XBI looks scary now, and move to $93.50 nears. But the formation of what appears to be double top is what worries me. The only question, where is the neckline in this mess? It is probably not $93.50, and that is good news. It looks to be in a range of $88 or $89, and break below that would confirm the double-top, and a move much lower.

xbi

Regeneron

Regeneron continued its downward move today after getting close to resistance around $351.

regeneron

Biogen

Biogen continues to try to turn higher.

biogen

Advertisements

AMD

There was a lot of activity again in AMD options with 142,000 put contracts trading at $10 strike price for April 20 expiration. According to data from Trade Alert,  52 percent of the volume occurred on the bid, and that would tell me someone was likely buying the puts, but we won’t know until open interest updates tomorrow. There was already open interest of 267k contracts. Meanwhile, the $11 puts also traded about 43,000 contracts, but again the open interest going into today was about 265k.

The chart is near a major breakdown, and should it fall through $11.20, it is likely to head towards $10.70, but it could be as much as $9.75

amd

Advertisements

Broadcom

Broadcom reported better than expected fiscal first-quarter revenue of $5.331 billion, ahead of estimates for 4.998 billion, while beating on EPS at $5.12 per share versus estimates of $5.06 according to thefly.com. The guidance for revenue of $5 billion for the fiscal second quarter is pretty much in line with expectations. To me, after the first look, there was nothing in this report that wasn’t as expected. I think the overall trend in Broadcom continues to stay favorable, with the stock continuing to rise.

broadcom


Twitter

Twitter is close to a big breakout and a rise above $36.75, as I noted in an Investopedia article, sends shares much higher, perhaps to $46. The holder of January 2019 $37 calls, pared their position back yesterday, with the open interest being reduced to 89,000 contracts.  The calls trade at $6.25, and that makes the open contracts worth about $55 million. Whoa! To think it was about $66 million yesterday before they sold some of those calls.

I went over this in the premium video yesterday and showed the build-up in the open interest when I think the position was first purchased.

Again, it surprises me how slow this trader is in lowering the position given the massive gains. In the article I wrote yesterday, I noted the open interest jumped around the end of August, and the price of Twitter was much lower, like in the upper-teens, which means the options were likely bought for a very cheap premium.

It makes me think they see more gains for the stock price.

 

twitter

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Join our 611 Daily Subscribers And Get This FREE Commentary In Your E-Mail! 

 

That is it!

Advertisements


Mott Capital’s Reading The Markets – An In-depth Global Macro Stock Market Commentary – In Video Format – See How Michael Dissects The Markets

Just $200 Per Year – Get Your Free 2 Week Trial

Recent Videos:

Looking At Twitter

More Upgrades On Amazon And Micron

Micron Jumps, Nvidia’s Breakout

Market Surges Breakouts All Over

Roku Borrow Rate Surge, Biotech Fakeout?

Tech And Biotech Look Weak, Plus Subscriber Mailbag

What The Heck Happened

 

Free Articles Written By Mike:

Alibaba Stock May Surge By 11%

Why Broadcom May Rise As Much As 17%

Twitter’s Soaring Stock May Go 25% Higher

Why Visa’s Stock May Rise 14% in 2018

Why Celgene’s Beaten Down Stock Can Rise 28%

Ford Options Traders Bet Stock Will Fall 25% This Year

Biogen’s Bargain Price May Spur a 14% Stock Gain

Qualcomm Poised For 20% Drop After Broadcom Deal Halted

Nvidia’s Breakout Seen Fueling 14% Stock Gain

Why Overvalued Gilead May Fall 10%

3 Chip Stocks Poised to Rise as Much as 26%

Facebook Seen Rising 20% Defying Skeptics

Roku Shares Could Fall 50% Further

Why Micron’s Stock Bulls May Be Wrong

Why Bank Stocks Are Ready for a Short-Term Pullback

 

Join our 611 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

-OR-

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]

Photo credit via Flickr

Michael Kramer and the clients of Mott Capital own shares of ACAD, TSLA

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #sp500 #biotech #biogen #regeneron #twitter #amd #broadcom  

roku acadia biogen nvidia tesla

Roku’s Borrow Rate Rises, plus Biogen, Acadia, Tesla, and Nvidia


Roku’s Borrow Rate Rises, plus Biogen, Acadia, Tesla, and Nvidia

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Join our 611 Daily Subscribers And Get This FREE Commentary In Your E-Mail! 

 

 

The sell-off continued again with the S&P 500 trading down to roughly 2,646, where a sturdy level of support lies. So for now, it looks like we have held, and my guess is that we could have another few points to the downside at most, and I expect that we turn higher again.

Mott Capital Management, Michael Kramer

Mott Capital’s Reading The Markets

An In-depth Global Macro Premium Stock Market Commentary

In Video Format- See How Michael Dissects The Markets

Premium Subscription Based Membership

Just $200 Per Year – Get Your Free 2 Week Trial

Let Michael help you! Have questions? Let Michael help you find the answer. Sign-up and get two weeks free: Watch the latest video: Looking At Twitter

Biotech

Biotech shares have also found some support around $113.75 on the broader NASDAQ Biotech $IBB ETF. I drew in a downtrend, just because it seems prudent at this point to do so, from the peak at $119.25 to $115.70. The breakout from the past week seems convincing enough to me to think we begin moving higher.

biotech

The XBI also failed at resistance, and we have seen a retracement the past couple of days as well. For now, the setup is still bullish, and if the pullback extends to $93.60, it is not the end of the world.

biotech


Incyte

Incyte shares have pulled back too, bringing into question the breakout. But for now, the pullback appears to be a fill the gap scenario more than a then a failed breakout. Tomorrow will be telling.

incy


Regeneron

Regeneron shares have risen, but a big test looms at $352 with an intense level of resistance waiting, my guess resistance holds, and the stock moves lower.

regeneron


Acadia

Acadia shares fell hard in recent days but have held support at around $25, and I think that means shares could be headed back towards $26.5. My hunch or gut feeling, as we approach the depression data later this fall, we may see some buyers or traders looking to cover short ahead of the news, and that could help to lift the price. Short Interest stood at roughly 10.3 million as of February 28.

acadia

Biogen

Biogen shares also started to bounce a bit too. It would be a positive should this stock start rising again for the group.

biogen


Roku

Roku’s borrow rate continues to surge, according to TradeAlert, the rate is over 100 percent. Insane.

 

Roku

In fact, we can also see the implied volatility levels on the options are rising the further into the future one goes.  It would suggest that traders are betting on the volatility in the stock to continuing rising, and thus the risk in the stock is rising as well.

roku

As of the February 28, short-interest surged to 9.946 million shares, representing 63.5 percent of the float!  That is massive!

ROKU Short Interest Chart

ROKU Short Interest data by YCharts

Advertisements

AMD

AMD shares are entering a danger zone, with the stock moving towards the cusp of a breakdown. The $11.20 technical support significant, a break below send the price towards the $10.50 region.

 

amd

Tesla

In the latest round of Tesla drama, CNBC is reporting that the company is churning out flawed parts. When I saw this, I was like “is the old news or new news?” That is right it was just at the end of January they reported batteries were being put together by hand.

I’m not sure what the delivery rates or how batteries are being assembled, I’m not even sure today’s news is even new? It sounds a lot like old news. But it doesn’t matter because the stock went down as a result.

Somebody made a big bet share would fall to about $250 bucks today, with the purchase of about 4,000 contracts of the April $250 puts. The notional value is only about $500k. Not huge, but undoubtedly interesting.


Nvidia

Today was RBC’s turn to raise its price target on NVIDIA, by an astonishing $5 to $285, talk about sticking your neck out there. But what I find interest is that price adjustment comes despite Nvidia potentially facing a notable slowdown in cryptocurrency benefits. But of course, they see a scenario of $12+ in earnings per share by the year the year 2021, on data center and gaming! That is nearly $2.50 ABOVE consensus of $9.50 per share. So why only give the stock 15 percent upside, if you are looking for earning to come in 26% higher than consensus. I don’t know. Sorry, I don’t get it.

Until Tomorrow! Good Luck!

Advertisements


Mott Capital’s Reading The Markets – An In-depth Global Macro Stock Market Commentary – In Video Format – See How Michael Dissects The Markets

Just $200 Per Year – Get Your Free 2 Week Trial

Recent Videos:

Looking At Twitter

More Upgrades On Amazon And Micron

Micron Jumps, Nvidia’s Breakout

Market Surges Breakouts All Over

Roku Borrow Rate Surge, Biotech Fakeout?

Tech And Biotech Look Weak, Plus Subscriber Mailbag

What The Heck Happened

 

Free Articles Written By Mike:

Why Visa’s Stock May Rise 14% in 2018

Why Celgene’s Beaten Down Stock Can Rise 28%

Ford Options Traders Bet Stock Will Fall 25% This Year

Biogen’s Bargain Price May Spur a 14% Stock Gain

Qualcomm Poised For 20% Drop After Broadcom Deal Halted

Nvidia’s Breakout Seen Fueling 14% Stock Gain

Why Overvalued Gilead May Fall 10%

3 Chip Stocks Poised to Rise as Much as 26%

Facebook Seen Rising 20% Defying Skeptics

Roku Shares Could Fall 50% Further

Why Micron’s Stock Bulls May Be Wrong

Why Bank Stocks Are Ready for a Short-Term Pullback

 

Join our 611 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

-OR-

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]

Photo credit via Flickr

Michael Kramer and the clients of Mott Capital own shares of ACAD, TSLA

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #sp500 #technology #roku #tesla #nvidia #biotech #biogen #incyte #acadia  

Micron’s Massive Breakout, Plus Skyworks, Lam, Biogen, Alnylam & More


Micron’s Massive Breakout, Plus Skyworks, Lam, Biogen, Alnylam & More

The stock market was mixed on Monday, with the S&P 500 finishing the day down slightly. Technology and Biotechnology continue to be the best performing sectors in the market, with the Nasdaq Biotech IBB rising by 40 bps, and the Technology ETF XLK rising by 45 bps. The semiconductor ETF SOXX was the best performing group up another over 1 percent.

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Join our 611 Daily Subscribers And Get This FREE Commentary In Your E-Mail! 

 

Mott Capital Management, Michael Kramer

Mott Capital’s Reading The Markets

An In-depth Global Macro Premium Stock Market Commentary

In Video Format- See How Michael Dissects The Markets

Premium Subscription Based Membership

Just $200 Per Year – Get Your Free 2 Week Trial

Micron

Micron’s stock was the most prominent winner up by nearly 9 percent, with the stock eclipsing the $58 technical level we had been targeting for some time. The move higher came after Nomura raised its price target on the stock to amazing $100, nearly doubling its previous target of $55. Meanwhile, Evercore upgraded the stock to $80 from $60.

If you are a Micron bull, then the good news, is the next resistance level comes somewhere around $68.

micron

Option volume was also very bullish today as well, with nearly 41,000 call contracts trading at the $55 strike price, an implies a breakeven price of nearly $62. Meanwhile, 30,000 calls contracts traded at the $60, and implies a breakeven price of nearly $64.

micron options


Skyworks

Skyworks has quietly worked its way back to nearly an all-time high. So much for the Apple supercycle issues. That is likely because Skyworks continues to diversify its customers away from Apple and continues to drive earnings and revenue growth.

skworks


Lam

Lam Research broke out, rising above its previous high, on surging volume.  Could shares climb all the way to $250? It doesn’t seem outside of the realm of possibility.

lam reserarch

 

Biogen

Biogen shares better find a bounce or the final nail may be put in the coffin of this stock. The stock sits on it technical support level around $280, and should this break below $275; it is likely headed another 11 percent lower, towards $250.

biogen

Alnylam

Shares of Alnylam broke out today, crossing above $139.50 its previous all-time high.

anylam

If the old guard biotechs aren’t going to lead the group higher, other companies are going to have to pick up the slack. Today it was Alnylam, Alkermes, and Seattle Genetics turn.

Advertisements

Alkermes

Alkermes has been floating above and below the $60 mark for some time, and it will be interesting to see if the stock can finally pull away to the upside. There is only a little bit of open interest at the May 2018 calls at the $60 strike price, with 1,700 contracts open. The calls cost about $5.00 bucks It is small bet, with a notional value of approximately $1.0 million, but the options are expensive with an implied volatility of nearly 48 percent. The stock would have to rise to about $65 to break even.

biotech

Seattle Genetics

Seattle Genetics is either close to a massive breakout or colossal breakdown. It looks a like a symmetrical triangle in the chart, and that would suggest a continuation of the prior uptrend. A Rise above $60 could bring the breakout.

 

seattle genetics

Advertisements

Charter

Charter, the cable company, is a new one for us to explore and was one of the better consumer discretionary names today. The chart has a strong set-up. We will have to keep an eye.

charter

That’s It.

Advertisements


Mott Capital’s Reading The Markets – An In-depth Global Macro Stock Market Commentary – In Video Format – See How Michael Dissects The Markets

Just $200 Per Year – Get Your Free 2 Week Trial

Recent Videos:

Micron Jumps, Nvidia’s Breakout

Market Surges Breakouts All Over

Roku Borrow Rate Surge, Biotech Fakeout?

Tech And Biotech Look Weak, Plus Subscriber Mailbag

What The Heck Happened

 

Free Articles Written By Mike:

Nvidia’s Breakout Seen Fueling 14% Stock Gain

Why Overvalued Gilead May Fall 10%

3 Chip Stocks Poised to Rise as Much as 26%

Facebook Seen Rising 20% Defying Skeptics

Roku Shares Could Fall 50% Further

Why Micron’s Stock Bulls May Be Wrong

Why Bank Stocks Are Ready for a Short-Term Pullback

 

Join our 611 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

-OR-

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]

Photo credit via Flickr

Michael Kramer and the clients of Mott Capital own shares of SWKS, ALKS

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #sp500 #biotech #technology #micron #lam #skyworks #biogen #alnylam #alkermes #charter

stock market bull

Biotech and Tech Stocks Are Approaching Make Or Break Moments


Biotech and Tech Stocks Are Approaching Make Or Break Moments

The stock market picked right up from where it left off last week, with the S&P 500 continuing to surging to 2,721 up about 1.1 percent today. Based on the charts, it seems like we have a pretty good shot of continuing to rise to somewhere between 2,740 and 2,760 before we see a significant region of resistance again.

Mott Capital Management, Michael Kramer

Mott Capital’s Reading The Markets

An In-depth Global Macro Premium Stock Market Commentary

In Video Format- See How Michael Dissects The Markets

Premium Subscription Based Membership

Just $200 Per Year – Get Your Free 2 Week Trial

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Join our 611 Daily Subscribers And Get This FREE Commentary In Your E-Mail! 

 

S&P 500


Yields

I still think 10-year treasury rates continue to decline, and I still believe we see a push down back towards 2.6 percent. The chart has turned, and it seems a new trend lower has formed.

treasury yields

Inflation Watch

The inflation number to watch this week will be average hourly wages released during the Job report on Friday morning. According to Bloomberg, estimates are calling for y/y hourly wage growth of 2.9 percent, and consensus is in a range of 2.8 to 3.0 percent.

Advertisements

Biotech Sector

The NASDAQ Biotech ETF IBB has an unusual setup in the chart, with resistance at $111.50. The formation doesn’t look the greatest. In fact, should it the ETF fail again to rise above $111.50 I would grow very concerned about the future direction of the group.

biotech

The same setup is confirmed in the XBI as well. what had once been a promising year is beginning to look worrisome.

biotech

It is always important to watch how stocks “act” in a big up day, especially when there is buying across all the sectors. But look at what stocks hardly budge. Celgene, Biogen, and Gilead. Only Amgen performed well of the big biotech names, and that seems concerning. It likely means all the sellers have not been shaken out of the group yet.

Biogen shares are trying their hardest to bottom. The relative strength index (RSI) is near oversold levels at roughly 33. There is a slight hint of the RSI starting to trend higher while the stock price continues to test the lows, which could be a bullish divergence. But it may be a bit to early to say for certain.

biogen


Technology

The technology ETF (XLK) has the making of what appears to be a double top. It makes the $69.25 level of critical importance. The RSI has been trending lower for sometime with a series of lower highs, and lower lowers. Again, we need to see the XLK continue to rise, in the near-term, and rise above $69.25.

technology sector

Apple

Apple has the making of a similar double top, although it is not nearly as pronounced as the XLK.

apple

Microsoft

Microsoft is another example, with the same double top setup. It makes the $95.25 level extremely important for the stock. Notice how the RSI has been trending lower, while volume has been steadily declining. To confirm a breakout at $95.25 we need to see a meaningful surge in volume. On the other side, should MSFT fall below $85, it would likely be confirmation of the double top pattern.

microsoft

NASDAQ 100

The biggest problem is that NASDAQ 100 is exhibiting the same pattern.

ndx

Advertisements

Micron

One stock that has broken out is Micron. I noted over the weekend the importance of $50, and it easily broke out today, surging by nearly 6 percent. Notice how volume surged and has been steadily increasing since early February, along with a rising RSI. As we have noted it before, the stocks next stop could be around $58.

micron

Netflix

Netflix is also in breakout mode, with  its shares climbing today as well, and are now at $315, up nearly 4.5 percent. Notice again increasing levels of volume, and an RSI trending higher.  The stock got another price target upgrade today, this time it was Macquarie. The firm raised it price target to $330 from $276.

netflix

I hope I was able to show the subtle difference in the charts, and why I have some level of concern and will be keeping a very close eye on things.

That’s it!

 

Mott Capital’s Reading The Markets – An In-depth Global Macro Stock Market Commentary – In Video Format – See How Michael Dissects The Markets

Just $200 Per Year – Get Your Free 2 Week Trial

Recent Videos:

What The Heck Happened

Breaking Down Acadia’s Results, Exploring Trends In Chips Stocks

Stocks In Rally Mode, More To Come

Crazy Market Reaction Following Fed Minutes, Plus Subscriber Mail Bag

Subscriber Mailbag, Plus Market Rundown

Free Articles Written By Mike:

Micron May Rise 12% As Analysts Grow More Bullish

Why Amazon’s Stock May Continue To Outperform Alibaba’s

AMD May Fall 17% as Bearish Option Volume Soars

McDonald’s Stock Nears Bear Market Levels

4 Bargain Chip Stocks

3 Biotech Stocks That May Be On The Verge Of Sharp Declines

Roku Short Sellers Are Piling In Even As Stock Falls

Nvidia’s Stock May Be A Bargain As Earnings Forecasts Explode

6 Bargain Stocks Hidden in Market’s Rebound

Gilead’s Stock Rebound May Stall As Analysts Cut Forecasts

Netflix Seen Rising 40% On International Growth

Why Chip Stocks Will Keep Rising

Exact Sciences’ Nightmare May Get Worse for Investors

Why Tesla’s Stock Can Soar to New Highs

Join our 611 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

-OR-

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]

Photo credit via Flickr

Michael Kramer and the clients of Mott Capital owns shares of NFLX and CELG

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #sp500 #micron #microsoft #biotech #celgene #biogen #gilead #amgen #netflix #micron #technology #yield

Acadia, Biogen, Celgene, Regeneron In Focus – A Look At The Week Ahead


Acadia, Biogen, Celgene, Regeneron In Focus – A Look At The Week Ahead

The stock market will look to build on last weeks gains, and it will be a week filled with economic data and Fed talk.

The one segment of the market rally that has been missing has been the biotech sector, and it is no wonder when stocks like Celgene, Biogen, and Regeneron have been in the gutter. Acadia gets a shot at breaking the negative news cycle this week and perhaps giving the group a boost.

Mott Capital Management, Michael Kramer

Mott Capital’s Reading The Markets

An In-depth Global Macro Premium Stock Market Commentary

In Video Format- See How Michael Dissects The Markets

Premium Subscription Based Membership

Just $200 Per Year – Get Your Free 2 Week Trial

Economic Outlook

Fed Chair Powell will speak to the House on Tuesday starting at 10 am while talking to the Senate on Thursday at 10 am. Fourth quarter GDP will come on Wednesday, and the consensus is looking for a reading of 2.5 percent. But the significant reading will occur on Thursday when we get Personal Income and Outlays. Personal Income is expected to have a reading of 0.3%, while PCE is expected to show a y/y gain of 1.7 percent, while core y/y is supposed to rise by 1.5 percent.

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Join our 611 Daily Subscribers And Get This FREE Commentary In Your E-Mail! 

 

Biotech

Biotech has been a weak group, and the internals for the leadership is nothing to write home about. Shares of Celgene, Biogen, and Regeneron have fallen on hard times, with these three stocks accounting for nearly 25 percent of the Nasdaq Biotech ETF (IBB) it is hard to imagine the group can advance much without them.


Celgene

Celgene shares have seen a disastrous fall from grace, shares have fallen by an astounding 35 percent from a high near $147 to almost $95.50. The company has made a number of moves to help bolster the pipeline and calm nerves around the dependence on Revlimid, recently announcing it would buy Juno, but still, shares have suffered. Admittedly, this one has gone against me, and I’m not thrilled with the outcome.

The good news is that the stock has managed to hold support around $94. The bad news is that every time it has shown a sign of life over the past few months the stock just goes the other way.

Celg

Despite the recent acquisitions, analysts have yet to up their revenue targets, remaining reasonably flat, while trading at Gilead type of valuations of 9.3 times 2019 earnings estimate of $10.22.

CELG Revenue Estimates for Current Fiscal Year Chart

CELG Revenue Estimates for Current Fiscal Year data by YCharts

Advertisements

Biogen

Biogen shares are in the same camp, having fallen from nearly $370 to $283, a decline of 23 percent. On February 7, the company announced it would stop developing Tysabri to treat acute ischemic stroke patients. Then adding insult to injury, one week later the company announced it would be adding patients to its trial in Alzheimer’s disease drug for aducanumab, creating more fear.

biogen

The chart like Celgene shows the stock has gotten to critical support to $282. It had seemed for some time that Biogen was destined to reach $400, but the negative news flow has just changed that direction.


Regeneron

Regeneron shares have broken down, and what had been a failed breakout attempt, now puts shares in of danger of heading lower to $273.

 

regeneron

Advertisements

Acadia

Acadia will post fourth-quarter results on Tuesday. Analysts are looking for the company to report that revenue climbed by over 275 percent in the fourth quarter to $45.18 million, on a loss of $0.57. More important will be any commentary on 2018 guidance, where analysts are looking for revenue of $253 million.

When looking at the current run rate of quarterly revenue growth, we can see the growth has been relatively linear. Should revenue come in at analysts estimates or higher, it would continue to put the company on pace to have revenue of $300 million in 2018, about $50 million more than expectations, but we will surely find out more details

acadia

The stock has been a bust for years now, and it seems that every piece of positive news has been met with selling pressure.

acadia

Will something change soon? Hopefully, but at this point frustration with this stock runs deep. It feels as though every time I think the stock is about to breakout, it fails. My expectations for revenue growth are solid when it comes to the quarter and next year. But when it comes to how the stock will perform, I  at a loss, and tired of guessing, getting my hopes to only be met with disappointment.

If the fundamentals continue to improve, one has to believe one day it will be reflected in the stock price.

Good luck his week.

Mott Capital’s Reading The Markets – An In-depth Global Macro Stock Market Commentary – In Video Format – See How Michael Dissects The Markets

Just $200 Per Year – Get Your Free 2 Week Trial

Recent Videos:

Stock Market Still Not Out Of Danger Zone

Crazy Market Reaction Following Fed Minutes, Plus Subscriber Mail Bag

Subscriber Mailbag, Plus Market Rundown

Why Amazon Has Peaked And Tesla Could Be Cheap

Inflation Rising, Rates Rising, Stocks Do Not Care!

Stock Price Continue To Rebound, More To Come?

Stock Market Bouncing Back

Free Articles Written By Mike:

AMD Analysts See 20% Stock Gain Despite Red Flags

PayPal Seen Falling 15% on Loss of Biggest Customer

How Costco’s Stock Can Soar On E-Commerce

Roku’s Stock May Fall 35% Further As Sales Stall

3 Commodity Stocks That May Soar 20% on Inflation

Why Walmart Will Never Be Amazon

eBay’s Lagging Stock Set To Rise On Revenue Growth

Biotech Alkermes May Surge On Wave of New Drugs

Apple Options Traders Bet Big On 15% Share Gain

Why Chip Stocks Are Still Cheap

Disney’s Stock Looks Like a Bargain

Chipotle’s Stock Rebound May Fizzle

Why Facebook’s Rally Is Lagging the Techs

Join our 611 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

-OR-

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]

Photo Credit Via Flickr

Michael Kramer and the Clients of Mott Capial own shares of CELG and ACAD

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #sp500 #stocks #biotech #celgene #acadia #regeneron #biogen

biotech stocks

Biotech Stocks Continue To Soar, More Gains To Come

Advertisements

Biotech Stocks Continue To Soar, More Gains To Come

Mott Capital Management, Michael Kramer

Mott Capital’s Reading The Markets

An In-depth Global Macro Premium Stock Market Commentary

In Video Format- See How Michael Dissects The Markets

Premium Subscription Based Membership

Just $200 Per Year – Get Your Free 2 Week Trial

Biotech stocks continue to soar, and Biogen and Gilead had big days on Friday. Biogen jumped by nearly 4 percent, taking shares up $368, after reporting robust result on Thursday. Gilead shares jumped by over 5 percent, to over $85, after getting an upgrade from Jefferies and a price target increase to $95.

We have been talking about these two stocks for some time, and the breakout shouldn’t surprise anyone. It seems like the other day when we were focused on Biogen breaking over $318, and Gilead potentially rising to $82.

There appears to be very little standing in the way from Biogen rising to about $400 from its current level.

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Join our 611 Daily Subscribers And Get This FREE Commentary In Your E-Mail! 

 

biogen

Gilead also has very little standing between its current price and a rise to $92 as well, but that, of course, doesn’t mean it happens in a straight line.

gilead

Regeneron shares have moved out of its downtrend for the first time since June of 2017. That could help the stock rise to about $420. We can see in the chart the stock test the downtrend and it bounced. With the strength of the sector, the setup looks good.

regenernon

Alexion shares also look close to a big breakout, and could see a rise to about $145.

alxnAcadia has cleared two big hurdles, first breaking above a multi-month downtrend, and then resistance above $31. Next up a multi-year downtrend around $34, which could send shares to about $40.

Vertex has also seen its shares rise substantially.

vertex

With many of the big biotech stocks coming back and primed for more gains, the sector is likely not finished rising.

Mott Capital’s Reading The Markets – An In-depth Global Macro Stock Market Commentary – In Video Format – See How Michael Dissects The Markets

Just $200 Per Year – Get Your Free Trial

Recent Videos:

Dollar Breaking Down, Biotech And Intel Breakout

Why Apple May Not Be Toast Afterall

Why It May Be Time To Get Bullish On Materials As Dollar Plunges

What Everyone Seems To Get Wrong On Netflix

The Long Straddle, Plus Biotech Breakout

Subscriber Mail Bag

Euro’s Big Breakout

Inflation, Tesla Plus So Much More

Predicting The Euro’s Rise 


Free Articles Written By Mike:

Intel’s Massive Breakout Could Fuel Stock’s 25% Rise

Starbucks Stock Price Reflects Perception, Not Reality

Why AMD’s Soaring Stock May See a Sharp Pullback

Why Netflix Is Still Cheap Despite 30% Gain In Three Weeks

Why Micron’s 2018 Stock Gains Won’t Last

Apple’s Stock Outlook Overwhelmingly Bullish, Options Indicate

How Netflix Will Spark The Next Media M&A Wave

Biotech M&A Spree Could Push Sector to New Record Highs

Why Apple’s Suppliers Are Plunging As Mega Tech Thrives

Why Chipmaker Lam Research Is Poised For a Rebound

How a Juno Takeover Could Boost Celgene

Why Ford Could Rise By Nearly 30%

Apple Poised to Gain 14%, Defying Skeptics

Exxon Mobil May Rise 20% on the Back of Surging Oil

We offer daily market commentaries sent directly to your inbox or follow us on Twitter.

Join our 611 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

-OR-

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]

Photo Credit Via Flickr

Michael Kramer and the clients of Mott Capital own shares of ACAD

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2017 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #biotech #stocks #biogen #gilead #acadia #regeneron #vertex #alexion

 

Biotech stocks

Why Biotech Stocks Will Continue To Reach Record Heights

Advertisements

Why Biotech Stocks Will Continue To Reach Record Heights

Mott Capital Management, Michael Kramer

Mott Capital’s Reading The Markets

An In-depth Global Macro Premium Stock Market Commentary

In Video Format- See How Michael Dissects The Markets

Premium Subscription Based Membership

Just $200 Per Year – Get Your Free 2 Week Trial

Biotech stocks continue to rip higher, with the S&P Biotech ETF ($XBI) reaching a new record high, and the Nasdaq Biotech ETF ($IBB) quickly running to $122.

The XBI is now up by over 12 percent on the year, while the IBB is up about 10 percent, and the rally in both appears likely to continue. The IBB has little if any resistance standing in its way, until $122.

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”] 

Join our 611 Daily Subscribers And Get This Commentary In Your E-Mail! 

biotech

When looking at the components of the XBI, we can see that only three stocks out of the top 25 are down so far in 2018. While the big gainers have obviously been Juno and Bioverativ, others such as Loxo Oncology ($LOXO), Array Biosciences ( $ARRY), and Radius Health ($RDUS), have all jumped by over 20 percent.

Gilead

While the big names like Gilead ($GILD), Biogen ($BIIB), and Amgen ($AMGN) are not among the big gainers, they are putting together solid years. Gilead has jumped by roughly 13 percent and appears poised to continue to rise.

The chart below shows how Gilead shares cleared a critical resistance level around $80, and that could set the stage for a rise towards $90.

Amgen

Amgen shares have also surged to record highs as well and likely has more gains ahead as well. Plus it will now have strong support around $191 to $192 going forward.

amgn

Biogen

Biogen shares are nearing a massive breakout, one which could send the stock much higher, with the potential to rise to all-time highs. A rise above $355  sets the stage for the breakout. The company is set to report results on January 25, before the open.

biogen

Acadia

Even shares of struggling Acadia ($ACAD) are breaking out of a multi-month down trend, and what appears to a firm double bottom now in place, perhaps we can see this stock have a multi-year breakout, should it share price rise above $34.

acadiaWith M&A coming back to the front center, the biotech stocks are starting to see life again.

Mott Capital’s Reading The Markets – An In-depth Global Macro Stock Market Commentary – In Video Format – See How Michael Dissects The Markets

Just $200 Per Year – Get Your Free Trial

Recent Videos:

What Everyone Seems To Get Wrong On Netflix

The Long Straddle, Plus Biotech Breakout

Subscriber Mail Bag

Euro’s Big Breakout

Inflation, Tesla Plus So Much More

Predicting The Euro’s Rise 


Free Articles Written By Mike:

Why Amazon’s Stock Is Surging 15% Ahead Of Earnings

How Netflix Will Spark The Next Media M&A Wave

Biotech M&A Spree Could Push Sector to New Record Highs

Why Apple’s Suppliers Are Plunging As Mega Tech Thrives

Why A Rising Stock Market Isn’t Risky

Why Chipmaker Lam Research Is Poised For a Rebound

How a Juno Takeover Could Boost Celgene

Why Ford Could Rise By Nearly 30%

Why Morgan Stanley’s Stock Is Poised to Rise by 25%

Apple Poised to Gain 14%, Defying Skeptics

Exxon Mobil May Rise 20% on the Back of Surging Oil

We offer daily market commentaries sent directly to your inbox or follow us on Twitter.

Join our 611 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

-OR-

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]

Photo Credit Via Flickr

Michael Kramer and the clients of Mott Capital own shares of ACAD, CELG and ALKS

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2017 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #biotech #stocks #acadia #celgene #amgen #biogen #gilead #loxo #array #radius

 

 

 

Biogen earnings preview

What The Market Thinks About Biogen’s Upcoming Results – Premium Content

What The Market Thinks About Biogen’s Upcoming Results

In this premium video, we take a look at what the market may be expecting when Biogen reports results on January 25.

 

Advertisements

Mott Capital Management, Michael Kramer

Mott Capital’s Reading The Markets

An In-depth Global Macro Premium Stock Market Commentary

In Video Format- See How Michael Dissects The Markets

Premium Subscription Based Membership

Just $200 Per Year – Get Your Free 2 Week Trial

Photo Credit Via Flickr

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2017 Mott Capital Management, LLC. Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: $BIIB #BIIB #Biogen #earnings #biotech

stocks

Under Armour, Bitcoin, AMD, Biogen, Gilead, Pfizer – Monster Commentary

Advertisements

Under Armour, Bitcoin, AMD, Biogen, Gilead, Pfizer – Monster Commentary

Mott Capital Management, Michael Kramer

Mott Capital’s Reading The Markets

An In-depth Global Macro Premium Stock Market Commentary

In Video Format- See How Michael Dissects The Markets

Premium Subscription Based Membership

Just $200 Per Year – Get Your Free 2 Week Trial

S&P 500

The S&P 500 had a relatively uneventful day, with the index finishing the day down less than 20 bps. But the thing to take note of is how the index has now failed right at 2,805 three times. Big deal? Likely not, and I would suspect we blow through that resistance tomorrow. The downside now is around 2,790, and with the start of significant earnings next week, I get the sense investor want go long into some of these upcoming results.

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”] 

Join our 611 Daily Subscribers And Get This Commentary In Your E-Mail! 

AMD

The AMD seller appears to have gone up to the $12.50 level now; they must have caught word of our commentary yesterday, that is a joke. But anyway the chart continues to tell the story, and for now, AMD shares seem to want to go higher.  Maybe the seller should try the $12.75 level tomorrow. (meant to be funny, laugh!)

amd

Biogen

Biogen shares continue to trend nicely higher, with the next big test for the stock looming around $355. That is where gap from years ago is entirely closed, and a rise above $355 likely sends Biogen’s stock on to all-time highs. Also, we can see the stock has some room to rise before the relative strength index (RSI) gets to overbought levels.

biogen

Gilead

Gilead shares have had a massive breakout and could be on their way back to $92. If Gilead and Biogen get moving, the rest of the sector follows.

Gilead

Pfizer

Have you seen Pfizer lately? The stock looks like it ready to breakout in a big way.

pfizer

Under Armour

Under Armour looks terrible here, with a clear breakdown and a stock price that appears ready to fall to $11.55.

under armour

Even fundamentally Under Armour is grossly overvalued. Shares trade at nearly 42 times 2019 earnings estimates of $0.32. Compare that to Nike’s 24 times, and Lulu’s 25 times.

UAA PE Ratio (Forward 1y) Chart

UAA PE Ratio (Forward 1y) data by YCharts

Even on an EV/EBITDA ratio, Under Armour is first now on par with Nike, and is still well north of Lulu. It comes down to simple common sense, does Under Amour deserve to trade at premium or on par with Nike? Not a chance.

UAA EV to EBITDA (Forward) Chart

UAA EV to EBITDA (Forward) data by YCharts

Bitcoin

This chart of Bitcoin tells it all. The crypto-currency broke support around 11,800 and then it failed to rise through when it acted as resistance. See ya at 7,700.

bitcoin

That’s it!

Sign-up for our premium content on Seeking Alpha Market Place – “Reading The Markets”  and a get Two Week Free Trial Period

Premium Content: Benefits include the ability to reach out to Mike with questions through a chat room, direct message, or comments. 

Now JUST $25 Per Month Or $200 Per Year – Get Your Free 2-Week Trial Now!

Subscriber Mail Bag

Euro’s Big Breakout

Inflation, Tesla Plus So Much More

Predicting The Euro’s Rise

 


Free Articles Written By Mike:

Why Exact Sciences Will Plunge Even Further

How a Juno Takeover Could Boost Celgene

Why Facebook Stock Looks Like a Bargain

Why Ford Could Rise By Nearly 30%

Why Morgan Stanley’s Stock Is Poised to Rise by 25%

Apple Poised to Gain 14%, Defying Skeptics

Exxon Mobil May Rise 20% on the Back of Surging Oil

Qualcomm’s Stock Heads to a Crossroads

We offer daily market commentaries sent directly to your inbox or follow us on Twitter.

Join our 611 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

-OR-

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]

Photo Credit Via Flickr

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2017 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #sp500 #bitcoin #amd #biogen #gilead #under #armour #nike #lululemon 

stocks stock market biotech

Stock Market Sells Off As Biotech Gets Rocked, Again!


Advertisements

Stock Market Sells Off As Biotech Gets Rocked, Again!

Just more of the same isn’t? Gap up at the open, then a slow drag lower the rest of the day. I hate days were the market just gaps up, what is the point? It always just fills the gap. You must avoid opens like the one day.

Could it be more obvious? The only difference today was that we managed to fill two gaps. It’s getting old that is for sure and just serves as more of an annoyance than anything fundamentally changing.

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]  

s&P 500 The real frustrating part in most of this is that the media seems to like to talk about “warnings signs,” making a bigger deal than it deserves.

Is the market “overbought?”, Technically yes, based on the relative strength index reading of 77,  because a reading over 70 is considered overbought. The last time I checked the market doesn’t go up in a straight line and a pullback is expected to happen.

I have surely been one of the more aggressive bulls on Wall Street, over the past two years, and I’m looking for a rise to 3,100 in 2018 on the S&P 500. More recently I have suggested we could see a rise to roughly 2,850 by the start of March. But at the current pace, we would have likely hit that number before the end of January. So I would welcome a period of sideways consolidation or even a 2-3 percent pullback.

Fundamentally, the equity market is not expensive. The S&P 500 operating earnings are estimated to climb by 10.5 percent in 2019 to $164.57. That estimate, provided by Dow Jones S&P Indices, was just lifted from $160.03 on December 31. Based on that, even at 2,775 the S&P 500 is only valued at 16.8 times 2019 operating earnings. At the end of the first quarter on March 31, 2017, the S&P was trading at 16.6 times 2018 operating earnings estimates. So even with the fast start to the year, the market is valued at the same level it was last year to the start the year. Should estimates keep trending higher, then the market is only getting cheaper if the pace of earnings is climbing faster than the speed of the market.

The economy continues to strengthen with GDPNow forecasting a reading of 3.2 percent in the fourth quarter of 2017. That would make three straight quarters of GDP growth higher than 3 percent. Economies globally appear on the mend, and to this bull, things are looking pretty good.

So much for the naysayers that said that US GDP could no longer grow at 3 percent. Not to rub it in the face of the “economist”, but I did call this move higher in the economy in May of 2017.  For that matter, I see a four handle coming in 2018.

Biotech Stocks

The NASDAQ Biotech ETF ($IBB) was greeted with some resistance when they got to $113.50, no surprises, right? We can see it failed at that same level back in October, and it is going to have to battle to get through resistance. But we also know there is real support around $107, and the NASDAQ IBB is far from overbought at current levels.

ibbSurprisingly, 4 of the big 5 biotech stocks held there gains, with Amgen, Biogen, Gilead, and Regeneron all up. Only Celgene was down in that group. But look at the most significant losers today, they have also been among some of the most prominent gainers year to date. Plus just breaking tonight, Celgene is looking to acquire Juno according to the Wall Street Journal. Celgene isn’t messing around in 2018, and they are working very hard at diversifying that pipeline, the market seems so obsessed about.

Biotech

Roku

The air is really coming out of Roku now, and it is probably going to see a bounce back to $43, but don’t be fooled.

rokuThat gonna be it today.

Sign-up for our premium content on Seeking Alpha Market Place – “Reading The Markets”  and a get Two Week Free Trial Period

Premium Content: Benefits include the ability to reach out to Mike with questions through a chat room, direct message, or comments. 

Now JUST $25 Per Month Or $200 Per Year – Get Your Free 2-Week Trial Now!

Euro’s Big Breakout

Inflation, Tesla Plus So Much More

Predicting The Euro’s Rise

An Intelligent Way Of Looking At Tesla’s Results

3 Biotech Names To Start The Year

Disney- The Market Finally Get’s It

 


Free Articles Written By Mike:

Why Ford Could Rise By Nearly 30%

Why Morgan Stanley’s Stock Is Poised to Rise by 25%

Apple Poised to Gain 14%, Defying Skeptics

Exxon Mobil May Rise 20% on the Back of Surging Oil

Qualcomm’s Stock Heads to a Crossroads

We offer daily market commentaries sent directly to your inbox or follow us on Twitter.

Join our 611 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

-OR-

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]

Photo Credit Via Flickr

Michael Kramer and the Clients of Mott Capital own shares of CELG and TSLA

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2017 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #sp500 #bitoech #celgene #roku #biogen #amgen #gilead

bitcoin nvidia amd apple broadcom biotech

Bitcoin, AMD, Nvidia, Biotech, Could Apple iPhone Worries Be Overblown

Bitcoin, AMD, Nvidia, Biotech, Could Apple iPhone Worries Be Overblown

It is a new year, and with that everything gets reset back to zero, but other than not much else should change when trading opens again on January 2.

Bitcoin

It seems likely Bitcoin will continue its decline as well. In an Investopedia article on December 27, I wrote that Bitcoin could fall by as much as 50 percent, from its price of about 15,000, taking the cryptocurrency to nearly 7,700. With Bitcoin now is trading around 13,300, it seems there is still more downside risk.

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]

Join our 611 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

The Chart below shows how Bitcoin’s Relative Strength Index (RSI) is still far from oversold levels. The RSI is now around 46 and would need to fall below 30 before it was oversold. Meanwhile, the next significant level of resistance comes at roughly 11,800, and from there it is a long way down to around 7,700.

btc by Scorpio244 on TradingView.com

Nvidia and AMD Fallout

Nvidia and AMD will sometimes see their stock price get pushed around by the rise and fall of Bitcoin. It doesn’t matter whether GPU’s from AMD or Nvidia get used to mine Bitcoin or other cryptocurrencies, they are guilty by association because most investors aren’t going to have that type technical sophistication, so just keep that mind. y

In reality, as I have written about in the past, Nvidia’s total revenue from cryptocurrency mining was about 2 percent in the latest quarter, while AMD has started downplaying cryptocurrency trends in its business as well. In fact, AMD was down nearly 10 percent in 2017; the stock market never gave AMD any credit for Bitcoin when it was rising, so why should it when Bitcoin is falling.

NVDA Chart

NVDA data by YCharts

      

Tesla

Tesla Model 3’s are getting delivered, and you can now even buy one on eBay! In fact, you can also buy one now for $77,000! Or this one for $85,000!

Biotech

Remember the JP Morgan Healthcare Conference kicks-off on January 8, and there usually plenty of big announcements that come out of this conference, with more than 400 companies presenting. So make sure you are paying attention.

The Biotech ETF ($IBB) managed to stay in the zone of support, between $106.50 and $107. The biotech stocks should be able to hold this area of support and rally off it come next week.

IBB by Scorpio244 on TradingView.com

 

Celgene has been able to test support now on a few occasions at $102.5, and to this point has held.

celg by Scorpio244 on TradingView.com

 

Biogen has been able to hold support at $319.

biib by Scorpio244 on TradingView.com

 

Gilead is the real question mark in the group. After looking like it made a significant multi-year breakout back in July, and the big Kite acquisition in late summer, the stock has struggled. It seems to have found two level of support around $71.75.

gild by Scorpio244 on TradingView.com

Apple

The focus has come back to Apple and the supply chain again, as investors once again worry about iPhone demand. It is ridiculous that these rumors come up so often. This is what the third or fourth time now? Now the rumors are pointing 30 million units for the first quarter. I have no clue, what this number will be, but we can make an educated guess about how Apple may fare.

Broadcom is a major supplier to Apple and it reported it fiscal fourth quarter 2017 results back on December 6, for the period ended October 29, 2017. The company provided guidance for the fiscal first quarter of 2018, ending on February 4. The company gave strong guidance of $5.3 billion at the mid-point, about 11 percent higher than previous estimates.

AVGO Revenue Estimates for Current Quarter Chart

AVGO Revenue Estimates for Current Quarter data by YCharts

In its 10-K, Broadcom said it believes that Apple accounted for more than 20 percent of revenue in 2017, up from 15 percent in 2016.

Broadcom’s Fiscal First quarter ends on February 4, 2018, running through nearly the middle of the calendar first quarter. If Apple iPhone shipments in the first quarter are to drop from say 50 million units to 30 million units, why would Broadcom issues such strong guidance? Will there be a huge drop off in business in the second half of February and March for Apple? Perhaps. But it is just one other way to assess the situation and think outside of the box and think about all the possibilities.

Good Luck!


On-Demand Premium Content

In my premium video, I run through how the different sectors set up and where the ETF’s might rise or fall too. The video is about nine minutes long and I run through many charts, pulling a lot of pieces into the video for the start of 2018. It an instructional video, so you will see exactly what I’m looking at. 


We offer daily market commentaries sent directly to your inbox or follow us on Twitter.

Join our 611 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

-OR-

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]

Michael Kramer and the Clients of Mott Capital own shares of CELG and TSLA

Photo Credit Via Flickr

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2017 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #bitcoin #nvidia #amd #apple #broadcom #iphone #x #tesla #model #biotech #celgene #gilead #biogen

 

 

Tesla

Tesla and Biotech’s Have Soared, While Chips and Tech Still Struggle

Tesla and Biotech’s Have Soared, While Chips and Tech Still Struggle

The past couple of trading sessions have seen shares of Tesla rise from roughly $310 to $340, while biotechs have jumped from $102 to $107 on the IBB ETF.  Meanwhile, tech and chips have stabilized but are not out of the woods just yet.

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”][/vc_column][/vc_row] Join our 611 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

S&P 500

Stock prices continue to rise, with the S&P 500 getting closer to 2,700, and fast approaching the box we targeted just a few short weeks ago.

 

The S&P 500 is coming close to move above the February 2016- Brexit trendline we laid well over a year ago.  The two-hour chart below shows how that trend line became resistance a while back, and while the S&P 500 has been able to trade right along, has been unable to break above it.  Should the S&P 500 break above that trendline, my guess would be we see a meaningful acceleration in the price action of the market.

Tech

Tech shares have been able to retrace much of their losses from last week, but have not entirely escaped into safety. The downtrend in the Technology ETF ($XLK) is still very much present, and only a  rise above $64.80 would be a sign of the clear path higher.

Technology

Alphabet ($GOOGL) shares like the broader ETF have recovered much its losses but again has failed to break to new highs.

alphabet

Apple ($AAPL) shares are also still in a downtrend as well.

aapl

Microsoft shares have moved back towards all-time highs.

While Cisco ($CSCO) has also been able to continue to grind higher.


Sign-up for our premium content on Seeking Alpha Market Place – “Reading The Markets”  and a get Two Week Free Trial Period

Premium Content: Benefits include the ability to reach out to Mike with questions through a chat room, direct message, or comments. 

We will respond to questions in short order and will respond to questions with full-post or video segment, just not one or two-word answers. 

Just $40 per Month

Why The FANG’s Could Lead In 2018

Tech Wreck V12.4.17 – More Room Too Fall

Machines Break Loose

Why Tesla Could Double, And Nvidia Could Get Cut In Half

Why The S&P500 Could Melt-Up Into Year End

S&P 500 Breakout- 2700?

Nailing The Biotech Breakout

 


 Semiconductors

One group that has not even come close to recovering is the semiconductor sector, with stocks like Nvidia ($NVDA), Micron ($MU), and Skyworks ($SWKS), still trying to get some upward momentum.  Micron is the only stock that has started trending higher, but then shares of the failed miserably at resistance at $45.

Micron

Tesla

One stock that has broken out and started to shows signs of life is Tesla, with shares trading back to nearly $341 just over the past couple of sessions.

tesla

A move above resistance around the $341, could send shares materially higher, perhaps back into the $370’s. Remember, Tesla will report delivery numbers three days after quarter end, and all eyes will be on the model 3. Additionally, the semi-truck reservations have been picking up steam as well, with Pepsi being the latest to order 100 trucks reportedly.

Read: Why Tesla’s Stock Price Could Double in 2018

Biotech

The biotech group has also had a big rally, with shares moving once again back to resistance at $107.

Biotech

Shares of Celgene ($CELG) have continued to move higher and are now in the process of filling the gap, which could see shares of the stock rise back to nearly $120.

celg

Biogen ($BIIB)  appears headed back towards $355.

biogen

That is for today. Lots of material to cover, but had to play catch-up.

 

Back tomorrow.

Watch my interview with Cheddar

Top 3 Predictions for the 2018 Market

Seeking Alpha Author Michael Kramer joins Cheddar to give his top three predictions for 2018 market trends. The first one: Tesla will hit a $100 billion market cap! He explains why he’s comparing the auto company to Amazon in his analysis and prediction.

Free Articles Written By Mike:

Why Qualcomm May Have To Pay 20% or More For NXP

Facebook Shares May Rise 20%, Options Trades Indicate

These 2 Suppliers Can Survive Without Apple

FANGs Are Cheaper Than Soda and Burger Stocks

Why Visa and MasterCard May Have Fallen Too Far

Biotech Stocks May See a New M&A Wave in 2018

Why Tesla’s Stock Could Rally Into Yearend

Disney’s Stock Advance Could Be Just The Beginning

Netflix Shares Could Be Headed Lower

We offer a lot of great commentaries all week talking about the major and relevant market events. Be sure to subscribe to get all our free commentaries sent directly to your inbox or follow us on Twitter.

Join our 611 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

-OR-

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”][/vc_column][/vc_row]

Michael Kramer and the Clients of Mott Capital own shares of $TSLA $GOOGL $SWKS

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2017 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #sp500 #technology #biotech #tesla #celgene #biogen #alpahbet #microsoft #cisco #apple

 

chipmakers tesla biotech vix

The Week Ahead: Watching – The VIX, Nvidia, Micron, Tesla & Biotech

The Monster Week Ahead: Watching – The VIX, Nvidia, Micron, Tesla & Biotech

We could see a much more relaxed market than the one we saw last week. With Tax Reform now through the Senate, the odds seem fairly good that reconciliation can produce a tax bill to be signed by the President by year-end. That should give stocks  the confidence it needs to avoid any sharp declines. Stock like Nvidia, Micron, Tesla, and the biotech sector could be in focus.

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”][/vc_column][/vc_row] Join our 611 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

In terms of the political headline risk, that seem to always exist. But the original headlines that brought stocks lower on Friday seemed to have changed Friday night with a correction issued.  The political websites can address the matter; I have to make mention of it because the S&P 500 did fall by nearly 1.7 percent from to peak to trough at one point.  But stocks should feel calmer regarding this matter as well.

The Russell 2000 ETF ($IWM) was actually down by nearly 3 percent at the trough. Was the news a big deal? Yes.

^SPX Chart

^SPX data by YCharts


Sign-up for our premium content on Seeking Alpha Market Place – “Reading The Markets”  and a get Two Week Free Trial Period

Premium Content Is Great For College Students, Non-Professional, and Professional Investors. It is designed to focus on what institutional investors are watching, based on Mike’s 20 plus years of professional analytic, trading, and portfolio management career.

Premium Content: Benefits include the ability to reach out to Mike with questions through a chat room, direct message, or comments. 

We will respond to questions in short order and will respond to questions with full-post or video segment, just not one or two-word answers. 

Just $40 per Month

Machines Break Loose

Why Tesla Could Double, And Nvidia Could Get Cut In Half

Why The S&P500 Could Melt-Up Into Year End

S&P 500 Breakout- 2700?

Nailing The Biotech Breakout

 


Postive Signs

There was a positive that came out of Friday’s disaster,  that we learned the market has a substantial underlying bid it, one that merely likes to buy the dips. There will be a day when buy the dip becomes, sell it more aggressively. It will come.

VIX

Additionally, the VIX index shows just how concerned the market was by the end of the day on Friday,  which was no concern. Because by the close, the VIX was back to where to it started the day near 11.40, despite rising to nearly 14.25 intraday.

^VIX Chart

^VIX data by YCharts

Chip Stocks

The chipmakers were decimated during the week, with the PHLX Semiconductor ETF ($SOXX) down by nearly 6 percent, and stocks like Micron ($MU) down 15.5 percent, Lam Research ($LRCX) down almost 13.5 percent, and Nvidia ($NVDA) down by nearly 8.9 percent.

SOXX Price Chart

SOXX Price data by YCharts

How this group trades to start this week should be of particular interest. The group began getting some upward momentum towards the end of the day Friday, and it will be essential to see the sector continue that positive energy higher.

The best way to know if a bottom had been reached in this group would be a lower open, retesting the lows from Friday, and than a surge higher into the end of the day Monday.  It would serve as confirmation of the lows reached on Friday, and that a bottom was put in place.

Micron

Micron

For Micron it would mean retesting the lows around $40.50 and a rally taking shares above $42.

Nvidia

For Nvidia, it means retesting a price below $194, and close above and close above $201.

NVDA nvidia

Closing above $202 is very critical for Nvidia because shares of Nvidia have found themselves back in the rising wedge pattern it had been for most of 2017.  As the 5-minute chart shows above, the stock was unable to break out and rise above $202, and the upper resistance trend line of the wedge. This week for Nvidia is beyond crucial.

NVDA

Flip-Flop

It is a flip-flop from last week, because last week, we noted how stocks like Visa ($V) and Nvidia, were likely to lead the market higher heading into year-end. But like most investors and traders, the action and event of trading starting on Wednesday through the close on Friday blindsided me as well as many others. Which tell us that charts are great in the absence of news flow, but new News also trumps charts, and when the market has to reset, it will reset. So I reset, like or leave it.

Tesla

Tesla shares held up very well last week despite the volatility all over the marketplace. In fact, just look at the chart below and how the stock just stopped going down between $303 and $308. That level has been stable for Tesla since the quarterly results in mid-November.

If the stock can continue to hold this level and the broader market can regain its footing, I think Tesla could be set for a year-end rally. But I what do I know, I am likely the most bullish person on Tesla for 2018 on Wall Street, even MarketWatch noted my bullish stance, in their call of the day.

Biotech

If you want to know where Biotech is heading this week, watch Biogen and Celgene. Biogen shares broke-out last week and retested that breakout at the end of the week. The stock could be looking to fill the gap, next week.

biogen stocks

While Celgene also retested its breakout.

A good week for Biotech could mean a good week for stocks and the market.

Good Luck!

Free Articles Written By Mike: 

Stock Prices Plunge On Emotion, Not Reality

Nvidia, Micron, and Lam May Not Have Bottomed Yet

Why Gilead’s Highly Touted Stock Has No Upside

Why Under Armour Could Fall 65%

How Tax Cuts Could Boost Home Depot’s Stock

Nvidia Could Fall 60% After Bubble Bursts

Why Intel and Broadcom Are Still Cheap

Apple Will Rise 17% by June, Options Trades Indicate

Why Roku’s Rocketing Stock May Flame Out

Verizon’s Stock May Rise More Than 15% in 2018

Biotechs Celgene, Biogen May Rally Through Yearend

AMD May Have Bottomed, Stock Set to Rise

Macy’s, JC Penney Face More Declines, Options Trades Suggest

Why Tesla’s Plunging Stock Price Conceals A Bright Future

Why Disney and Comcast Should Fear Netflix

We offer a lot of great commentaries all week talking about the major and relevant market events. Be sure to subscribe to get all our free commentaries sent directly to your inbox or follow us on Twitter.

Join our 611 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

-OR-

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”][/vc_column][/vc_row]

Photo Credit Via Flickr

Michael Kramer and the Clients of Mott Capital own shares of  Tesla, Celgene

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2017 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #sp500 #vix #chipmakers #micron #nvidia #tesla #celgene #biogen #biotech #news #youtube #stocks #week #ahead